한글목차

트라스트주맙 바이오시밀러 시장 규모는 최근 비약적으로 확대되고 있습니다. 2025년 69억 달러에서 2026년에는 88억 6,000만 달러에 이르고, CAGR 28.5%의 성장이 전망되고 있습니다. 지난 몇 년간 성장 요인으로는 HER2 양성 유방암의 높은 발병률, 트라스투주맙의 특허권 만료, 항암제 비용 상승, 바이오시밀러의 규제 승인 경로, 병원 내 항암제 도입의 진전 등을 꼽을 수 있습니다.

트라스트주맙 바이오시밀러 시장 규모는 향후 몇 년간 급격한 성장이 전망됩니다. 2030년에는 244억 8,000만 달러에 이르고, CAGR은 28.9%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 암 발병률 증가, 위암 적응증 확대, 바이오시밀러에 대한 유리한 리베이트 제도, 의사들의 신뢰도 상승, 헬스케어 의료비 억제책 강화 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 종양학 분야에서 바이오시밀러의 급속한 보급, HER2 표적치료제 접근성 향상, 유방암 치료의 가격 경쟁, 병원 종양학 분야에서의 사용 확대, 바이오시밀러 전환 수용성 확대 등을 들 수 있습니다.

유방암과 위암 발병률 증가가 트러스트주맙 바이오시밀러 시장 성장에 기여하고 있습니다. 트러스트주맙 바이오시밀러는 인간상피세포성장인자수용체2(HER2) 과발현 유방암 및 전이성 위암 치료에 사용됩니다. 예를 들어, 미국암협회(미국에 본부를 둔 암 퇴치에 초점을 맞춘 자발적 건강 단체)에 따르면, 2023년 9월 기준 2023년 여성에서 약 297,790건의 침윤성 유방암이 새로 진단될 것으로 예상되며, 같은 해에 약 43,700명이 사망할 것으로 예상되고 있습니다. 발생될 것으로 예측됩니다. 또한, Cancer India에 따르면 유방암은 인도 여성에게 가장 흔한 암으로 전체 여성 암의 약 14%를 차지합니다. 그 결과, 유방암 및 위암 발생률 증가로 인해 고가 브랜드 치료제 대비 비용 절감 효과가 있는 트러스트주맙 바이오시밀러에 대한 수요가 증가하고 있으며, 이는 트러스트주맙 바이오시밀러 시장의 성장을 가속하고 있습니다.

시장의 주요 기업들은 미개척 지역에서 신제품 출시에 집중하는 경향이 강해지고 있으며, 이는 트러스트주맙 바이오시밀러 시장의 발전을 형성하고 있습니다. 이 분야에서 사업을 영위하는 기업들은 경쟁 우위를 유지하고 고객의 요구를 더 잘 충족시키기 위해 신제품 개발, 제휴, 지리적 및 제품 포트폴리오 확대 등 다양한 전략적 노력을 기울이고 있습니다. 예를 들어, 2024년 4월 미국 제약사 어코드 바이오파마는 허셉틴(트라스투주맙)의 바이오시밀러인 HERCESSI(트라스투주맙-strf)가 HER2 과발현 암(다형성) 치료제로 미국 식품의약국(FDA)의 승인을 받았다고 발표했습니다. 승인받았다고 발표했습니다. HERCESSI는 HER2 과발현 유방암, 전이성 유방암, 전이성 위암 또는 위식도 접합부 선암의 보조 치료에 적응증을 가지고 있습니다. HER2 양성 암은 일반적으로 진행이 빠른 암으로 표적치료에 좋은 반응을 보입니다. HERCESSI는 HER2 수용체에 결합하여 그 활성을 억제함으로써 암세포의 증식과 복제를 지연시키는 작용기전을 가지고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Trastuzumab biosimilar is a HER2-targeted therapeutic drug developed to treat early-stage and metastatic HER2-positive breast cancers. It is a monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2/neu) on cancer cells, thereby inactivating the receptor.

The main products in the trastuzumab biosimilars category include Ogivri, Herzuma, Ontruzant, Trazimera, and others. The various indications include adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, and others, and these products are distributed through hospital pharmacies and online pharmacies.

Tariffs have affected the trastuzumab biosimilars market by increasing costs for imported monoclonal antibody inputs and sterile manufacturing supplies. These pressures are most pronounced in hospital pharmacies across Asia Pacific and Europe where biosimilars are widely adopted. Distribution costs have risen due to tariffs on cold chain components. On the positive side, tariffs are encouraging regional biologics manufacturing and supporting local biosimilar production capacity expansion.

The trastuzumab biosimilars market research report is one of a series of new reports from The Business Research Company that provides trastuzumab biosimilars market statistics, including trastuzumab biosimilars industry global market size, regional shares, competitors with a trastuzumab biosimilars market share, detailed trastuzumab biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the trastuzumab biosimilars industry. This trastuzumab biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The trastuzumab biosimilars market size has grown exponentially in recent years. It will grow from $6.9 billion in 2025 to $8.86 billion in 2026 at a compound annual growth rate (CAGR) of 28.5%. The growth in the historic period can be attributed to high incidence of HER2 positive breast cancer, loss of trastuzumab patent exclusivity, rising oncology drug costs, regulatory biosimilar pathways, hospital oncology adoption.

The trastuzumab biosimilars market size is expected to see exponential growth in the next few years. It will grow to $24.48 billion in 2030 at a compound annual growth rate (CAGR) of 28.9%. The growth in the forecast period can be attributed to increasing cancer prevalence, expansion into gastric cancer indications, favorable reimbursement for biosimilars, growing physician confidence, rising healthcare cost containment efforts. Major trends in the forecast period include rapid uptake of oncology biosimilars, improved access to HER2 targeted therapies, price competition in breast cancer treatment, expansion of hospital oncology use, growing acceptance of biosimilar switching.

The increasing prevalence of breast and gastric cancer has contributed to the growth of the trastuzumab biosimilars market. Trastuzumab biosimilars are used in the treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer and metastatic gastric cancer. For example, in September 2023, according to the American Cancer Society, a US-based voluntary health organization focused on eliminating cancer, approximately 297,790 new cases of invasive breast cancer were expected to be diagnosed in women in 2023, with about 43,700 deaths occurring in the same year. Additionally, according to Cancer India, breast cancer is the most common cancer among women in India and accounts for around 14% of all cancers in women. As a result, the rising incidence of breast and gastric cancers is increasing demand for trastuzumab biosimilars, which offer cost savings compared with high-priced branded therapies, thereby driving the growth of the trastuzumab biosimilars market.

Key players in the market are increasingly concentrating on launching new products in untapped regions, which is shaping the development of the trastuzumab biosimilars market. Companies operating in this space are adopting various strategic initiatives, including new product development, partnerships, and geographic as well as product portfolio expansion, to maintain their competitive position and better meet customer needs. For instance, in April 2024, Accord BioPharma Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration had approved HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab), for the treatment of multiple forms of HER2-overexpressing cancer. HERCESSI is indicated for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. HER2-positive cancers are typically aggressive but respond well to targeted therapies. HERCESSI acts by binding to the HER2 receptor, blocking its activity and slowing the growth and replication of cancer cells.

In June 2025, Alvotech, an Iceland-based biotechnology company, acquired Xbrane Biopharma AB for $28.9 million. Through this acquisition, Alvotech aims to strengthen its research and development capabilities and establish a stronger presence within the Swedish life sciences ecosystem. Xbrane Biopharma AB is a Sweden-based biopharmaceutical company specializing in the development of biosimilars and long-acting injectable therapies.

Major companies operating in the trastuzumab biosimilars market are Pfizer Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy's Laboratories Limited, Torrent Pharmaceuticals Limited

North America was the largest region in the trastuzumab biosimilars market in 2025. Middle East is expected to be the fastest growing region in the trastuzumab biosimilars market report during the forecast period. The regions covered in the trastuzumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the trastuzumab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The trastuzumab biosimilars market consists of sales of herceptin, avastin, and Kanjinti. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Trastuzumab Biosimilars Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses trastuzumab biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for trastuzumab biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The trastuzumab biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Ogivri; Herzuma; Ontruzant; Trazimera; Other Products
• 2) By Indication: Adjuvant Breast Cancer; Metastatic Breast Cancer; Metastatic Gastric Cancer; Other Indications
• 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy
• Companies Mentioned: Pfizer Inc.; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Mylan NV; Fujifilm Kyowa Kirin Biologics Co. Ltd.; Innovent Biologics Inc.; STADA Arzneimittel AG; Apotex Inc.; Samsung Bioepis Co. Ltd.; Celltrion Inc.; Zydus Lifesciences Limited; BIOCAD; Shanghai Henlius Biotech Inc.; Biocon Limited; Alvotech Holdings S.A.; Polpharma Biologics S.A; EirGenix Inc.; Hetero Biopharma Limited; Mabion SA; ALTEOGEN Inc.; Prestige BioPharma Limited; AryoGen Pharmed Co. Ltd.; Intas Pharmaceuticals Limited; Glenmark Pharmaceuticals Ltd.; Dr. Reddy's Laboratories Limited; Torrent Pharmaceuticals Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Trastuzumab Biosimilars Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Trastuzumab Biosimilars Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Trastuzumab Biosimilars Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Trastuzumab Biosimilars Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rapid Uptake Of Oncology Biosimilars
  • 4.2.2 Improved Access To Her2 Targeted Therapies
  • 4.2.3 Price Competition In Breast Cancer Treatment
  • 4.2.4 Expansion Of Hospital Oncology Use
  • 4.2.5 Growing Acceptance Of Biosimilar Switching

5. Trastuzumab Biosimilars Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Oncology Clinics
• 5.3 Cancer Treatment Centers
• 5.4 Specialty Pharmacies
• 5.5 Academic Hospitals

6. Trastuzumab Biosimilars Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Trastuzumab Biosimilars Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Trastuzumab Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Trastuzumab Biosimilars Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Trastuzumab Biosimilars Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Trastuzumab Biosimilars Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Trastuzumab Biosimilars Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Trastuzumab Biosimilars Market Segmentation

• 9.1. Global Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ogivri, Herzuma, Ontruzant, Trazimera, Other Products
• 9.2. Global Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications
• 9.3. Global Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacy, Online Pharmacy

10. Trastuzumab Biosimilars Market Regional And Country Analysis

• 10.1. Global Trastuzumab Biosimilars Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Trastuzumab Biosimilars Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Trastuzumab Biosimilars Market

• 11.1. Asia-Pacific Trastuzumab Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Trastuzumab Biosimilars Market

• 12.1. China Trastuzumab Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Trastuzumab Biosimilars Market

• 13.1. India Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Trastuzumab Biosimilars Market

• 14.1. Japan Trastuzumab Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Trastuzumab Biosimilars Market

• 15.1. Australia Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Trastuzumab Biosimilars Market

• 16.1. Indonesia Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Trastuzumab Biosimilars Market

• 17.1. South Korea Trastuzumab Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Trastuzumab Biosimilars Market

• 18.1. Taiwan Trastuzumab Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Trastuzumab Biosimilars Market

• 19.1. South East Asia Trastuzumab Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Trastuzumab Biosimilars Market

• 20.1. Western Europe Trastuzumab Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Trastuzumab Biosimilars Market

• 21.1. UK Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Trastuzumab Biosimilars Market

• 22.1. Germany Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Trastuzumab Biosimilars Market

• 23.1. France Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Trastuzumab Biosimilars Market

• 24.1. Italy Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Trastuzumab Biosimilars Market

• 25.1. Spain Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Trastuzumab Biosimilars Market

• 26.1. Eastern Europe Trastuzumab Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Trastuzumab Biosimilars Market

• 27.1. Russia Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Trastuzumab Biosimilars Market

• 28.1. North America Trastuzumab Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Trastuzumab Biosimilars Market

• 29.1. USA Trastuzumab Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Trastuzumab Biosimilars Market

• 30.1. Canada Trastuzumab Biosimilars Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Trastuzumab Biosimilars Market

• 31.1. South America Trastuzumab Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Trastuzumab Biosimilars Market

• 32.1. Brazil Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Trastuzumab Biosimilars Market

• 33.1. Middle East Trastuzumab Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Trastuzumab Biosimilars Market

• 34.1. Africa Trastuzumab Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Trastuzumab Biosimilars Market, Segmentation By Product, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Trastuzumab Biosimilars Market Regulatory and Investment Landscape

36. Trastuzumab Biosimilars Market Competitive Landscape And Company Profiles

• 36.1. Trastuzumab Biosimilars Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Trastuzumab Biosimilars Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Trastuzumab Biosimilars Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Mylan NV Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Fujifilm Kyowa Kirin Biologics Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Trastuzumab Biosimilars Market Other Major And Innovative Companies

• Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA

38. Global Trastuzumab Biosimilars Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Trastuzumab Biosimilars Market

40. Trastuzumab Biosimilars Market High Potential Countries, Segments and Strategies

• 40.1 Trastuzumab Biosimilars Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Trastuzumab Biosimilars Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Trastuzumab Biosimilars Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer